Cortexyme, Inc.
269 E. Grand Avenue
South San Francisco
CA
94080
United States
Tel: 6508674547
Website: http://www.cortexyme.com/
Email: careers@cortexyme.com
104 articles with Cortexyme, Inc.
-
Cortexyme Successfully Completes Acquisition of Novosteo
5/20/2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.
-
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
5/20/2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors.
-
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
5/12/2022
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases.
-
Cortexyme Announces Agreement to Acquire Novosteo
5/10/2022
Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.
-
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
3/21/2022
Cortexyme, Inc. presented new target engagement and biomarker data from the GAIN Trial at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases.
-
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.
-
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
3/15/2022
Cortexyme, Inc. today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors.
-
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
3/14/2022
Cortexyme, Inc. announced that the company will participate at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases, which is a hybrid event taking place March 15-20, 2022 in Barcelona, Spain, as well as virtually.
-
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders
3/9/2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided an update on both proprietary preclinical research and peer-reviewed publications supporting the potential of atuzaginstat (COR388) to treat patients with high-risk oral potentially malignant disorders (OPMDs).
-
Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588
3/8/2022
Cortexyme, Inc. announced results from the single ascending dose portion of the Phase 1 clinical trial of its new drug candidate COR588, a next generation, oral, small-molecule lysine gingipain inhibitor in development for the treatment of diseases related to P. gingivalis infection.
-
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
2/1/2022
Cortexyme, Inc. today provided a business update and announced key milestones for 2022.
-
Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.
-
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
1/26/2022
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application.
-
Cortexyme said it plans to provide additional updates pending further talks with the FDA.
-
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
11/23/2021
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th.
-
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
11/11/2021
Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program today, Thursday, November 11, 2021.
-
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
11/4/2021
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
-
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
10/26/2021
Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).